Carboplatin + Paclitaxel

DRUG3 trials

Sponsors

European Organisation for Research and Treatment of Cancer - EORTC, Presage Biosciences, Sun Yat-sen University

Conditions

Head and Neck Squamous Cell CarcinomaOvarian CancerPlatinum Sensitive Ovarian Cancer (PSOC)Salivary Gland Cancer

Early Phase 1

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

CompletedNCT06062602

Presage BiosciencesHead and Neck Squamous Cell Carcinoma

Start: 2021-07-26End: 2022-11-15Updated: 2023-10-06

Phase 2

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

CompletedNCT01969578

European Organisation for Research and Treatment of Cancer - EORTCSalivary Gland Cancer

Start: 2015-09-24End: 2024-02-16Updated: 2024-11-05

Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Not yet recruitingNCT07776171

Sun Yat-sen UniversityOvarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)

Start: 2026-09-30End: 2030-05-30Target: 176Updated: 2026-08-20

Related Papers

Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578).

Journal of Clinical Oncology2018-05-201 citations